MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.24.00278

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.

Inui Naoki, Suzuki Takahito, Tanaka Kazuki, Karayama Masato, Inoue Yusuke, Mori Kazutaka, Yasui Hideki, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Matsuura Shun, Nishimoto Koji, Matsui Takashi, Asada Kazuhiro, Hashimoto Dai, Fujii Masato, Niwa Mitsuru, Uehara Masahiro, Matsuda Hiroyuki, Koda Keigo, Ikeda Masaki, Inami Nao, Tamiya Yutaro, Kato Masato, Nakano Hideki, Mino Yasuaki, Enomoto Noriyuki, Suda Takafumi

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy.

PATIENTS AND

METHODS

Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety.

RESULTS

In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, -1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity.

CONCLUSION

The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.

Для цитирования: Inui Naoki, Suzuki Takahito, Tanaka Kazuki, Karayama Masato, Inoue Yusuke, Mori Kazutaka, Yasui Hideki, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Fujisawa Tomoyuki, Matsuura Shun, Nishimoto Koji, Matsui Takashi, Asada Kazuhiro, Hashimoto Dai, Fujii Masato, Niwa Mitsuru, Uehara Masahiro, Matsuda Hiroyuki, Koda Keigo, Ikeda Masaki, Inami Nao, Tamiya Yutaro, Kato Masato, Nakano Hideki, Mino Yasuaki, Enomoto Noriyuki, Suda Takafumi. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. DOI: 10.1200/jco.24.00278.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.